Last reviewed · How we verify
Extended Imipenem
At a glance
| Generic name | Extended Imipenem |
|---|---|
| Also known as | Extended Infusion of Imipenem, PiSA |
| Sponsor | Coordinación de Investigación en Salud, Mexico |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections (PHASE3)
- Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study
- Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis (NA)
- Evidence Based Management of Acute Biliary Pancreatitis
- Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO (PHASE4)
- Pharmacodynamics Study of Imipenem in Patients With Ventilator Associated Pneumonia (PHASE4)
- Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli (PHASE4)
- Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Extended Imipenem CI brief — competitive landscape report
- Extended Imipenem updates RSS · CI watch RSS
- Coordinación de Investigación en Salud, Mexico portfolio CI